丁苯酞联合溶栓治疗进展性脑卒中患者的临床疗效及安全性分析

Clinical Efficacy and Safety of Butylphthalide Combined with Thrombolytic Therapy in Patients with Progressive Stroke

目的探索丁苯酞联合溶栓治疗进展性脑卒中患者的临床效果以及安全性分析。方法选择2017年10月—2018年7月在该院就诊的进展性脑卒中患者100例作为探究对象,实施信封随机分组模式进行分组,50例/组,分别给予常规方式治疗、丁苯酞联合溶栓治疗,比较2组临床效果、NIHSS评分、ADL评分、不良反应发生情况。结果①观察组基本治愈例数30例,对照组为20例(χ~2=4.000 0、P=0.045 5);②治疗后,观察组NIHSS评分、ADL评分分别为(11.54±1.25)分、(69.58±4.25)分,对照组NIHSS评分为(17.54±1.55)分、ADL评分为(50.24±5.56)分(t=21.306 6、P=0.000 1;t=19.541 1、P=0.000 1);③观察组不良反应发生例数有3例,对照组为4例(χ~2=0.153 6,P=0.695 1)。结论丁苯酞联合溶栓治疗进展性脑卒中患者效果显著,可应用。

Objective To explore the clinical efficacy and safety of butylphthalide combined with thrombolytic therapy in patients with progressive stroke.Methods From October 2017 to July 2018 The patients with progressive stroke in our hospital were selected as the target of investigation.Envelope random grouping mode was implemented,50 cases/group were given routine treatment and butylphthalide combined with thrombolytic therapy,comparing the clinical effects,NIHSS score,ADL score,and adverse reactions of the two groups.Results 1.The number of basic cure cases in the observation group:30 cases,20 cases in the control group(χ^2=4.000 0,P=0.045 5);2.after treatment,the NIHSS score and ADL score of the observation group were(11.54±1.25)points,(69.58±4.25)points,the control group had a NIHSS score of(17.54±1.55)points,an ADL score of(50.24±5.56)points(t=21.306 6、P=0.000 1;t=19.541 1、P=0.000 1);3.There were 3 cases of adverse reactions and 4 cases of the control group(χ^2=0.153 6,P=0.659 1).Conclusion The combination of butylphthalide and thrombolytic therapy in patients with progressive stroke is effective and applicable.